Abstract:ABSTRACT Monoclonal antibodies (mAbs) are an attractive therapeutic platform for the prevention and treatment of influenza virus infection. There are two major glycoproteins on the influenza virion surface: hemagglutinin (HA), which is responsible for viral attachment and entry, and neuraminidase (NA), which mediates viral egress by enzymatically cleaving sialic acid to release budding particles from the host cell surface. Broadly neutralizing antibodies (bNAbs) that target the conserved HA central stalk region, such as CR9114, can inhibit both viral entry and egress. More recently, broadly binding mAbs that engage and inhibit the NA active site, such as 1G01, have been described to prevent viral egress. Here, we engineered bispecific antibodies (bsAbs) that combine the variable domains of CR9114 and 1G01 into a single molecule and evaluated if simultaneous targeting of two different glycoproteins improved antiviral properties in vitro and in vivo . Several CR9114/1G01 bsAbs were generated with various configurations of the two sets of the variable domains (“bsAb formats”). We found that combinations employing the addition of a single-chain variable fragment in the hinge region of an IgG scaffold had the best properties in terms of expression, stability, and binding. Further characterization of selected bsAbs showed potent neutralizing and egress-inhibiting activity. One such bsAb (“hSC_CR9114_1G01”) provided higher levels of prophylactic protection from mortality and morbidity upon challenge with H1N1 than either of the parental mAbs at low dosing (1 mg/kg). These results highlight the potential use of bsAbs that simultaneously target HA and NA as new influenza immunotherapeutics. IMPORTANCE Infection by the influenza virus remains a global health burden. The approaches utilized here to augment the activity of broadly protective influenza virus antibodies may lead to a new class of immunotherapies with enhanced activity.

A Broadly Protective Therapeutic Antibody Against Influenza B Virus with Two Mechanisms of Action

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

Broadly protective human antibodies that target the active site of influenza virus neuraminidase

Two Escape Mechanisms of Influenza A Virus to A Broadly Neutralizing Stalk-Binding Antibody

Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3

Broadly neutralizing antibodies recognizing different antigenic epitopes act synergistically against the influenza B virus.

A pan-influenza antibody inhibiting neuraminidase via receptor mimicry

Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface

A broadly protective antibody that targets the flavivirus NS1 protein

A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase

CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase

Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

New Class of Broad-Spectrum Antivirals Improves Influenza Virus Vaccine Development

Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin

A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses

Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice